What is Haemonetics Corporation's earnings per share (EPS)?

Haemonetics Corporation (HAE) reported diluted earnings per share of $2.05 for fiscal year 2026. This represents a -38.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Haemonetics Corporation (HAE) Financials

HAE NYSE

Trailing 12 months to June 27, 2026

Revenue $1.4B +0.4% YoY

Net Income $96.3M -41.1% YoY

EPS (Diluted) $2.07 -36.7% YoY

Free Cash Flow $291.2M +53.9% YoY

Market Cap $5.4B as of Oct 26, 2026

Price / Sales 4.0x on $1.4B revenue, trailing 12 months to June 27, 2026

Price / Earnings 56.3x on $96.3M net income, trailing 12 months to June 27, 2026

Price / Book 6.5x on $837.1M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 27, 2026 Reported Aug 6, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HAE SEC filings page.

Haemonetics Corporation (HAE) reported $1.4B in revenue over the twelve months to Jun 27, 2026, up 0.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HAE FY2026 2026-10-25

FY2026 shows a business with better product-level economics, but overhead and heavier borrowing absorbed the improvement.

Gross margin reached 59.0% while operating margin fell 4.6 percentage points in FY2026; cheaper production therefore did not translate into operating earnings. Operating cash flow was 301.3% of net income, indicating reported earnings understated cash generation in that year.

Operating cash flow rose to $293M and free cash flow to $260M in FY2026. Capital expenditures fell to $32.8M, making the cash improvement look driven more by working-capital or other non-capital movements than by heavy reinvestment.

The balance sheet is more debt-dependent: debt-to-equity reached 1.5x and long-term debt rose to $1.2B. The current ratio recovered to 3.0x as current liabilities fell 51.1%, so short-term liquidity improved even while long-term financing became heavier.

Financial Health Signals

Financial Health Score 58/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Haemonetics Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Haemonetics Corporation has an operating margin of 11.8%, meaning the company retains $12 of operating profit per $100 of revenue. This strong profitability earns a score of 72/100, reflecting efficient cost management and pricing power. This is down from 16.3% the prior year.

Growth

Haemonetics Corporation's revenue declined 2.0% year-over-year, from $1.4B to $1.3B. This contraction results in a growth score of 34/100.

Leverage

Haemonetics Corporation has elevated debt relative to equity (D/E of 1.53), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 17/100, reflecting increased financial risk.

Liquidity

With a current ratio of 2.95, Haemonetics Corporation holds $2.95 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.

Cash Flow

Haemonetics Corporation converts 19.5% of revenue into free cash flow ($260.4M). This strong cash generation earns a score of 78/100.

Returns

Haemonetics Corporation earns a strong 12.2% return on equity (ROE), meaning it generates $12 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 67/100. This is down from 20.4% the prior year.

Altman Z-Score Safe

3.25

Haemonetics Corporation scores 3.25, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $5.4B against total liabilities of $1.6B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Haemonetics Corporation passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

3.01x

For every $1 of reported earnings, Haemonetics Corporation generates $3.01 in operating cash flow ($293.2M OCF vs $97.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

8.12x

Haemonetics Corporation earns $8.12 in operating income for every $1 of interest expense ($156.7M vs $19.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$339.4M

YoY+5.6%

QoQ-2.0%

5Y CAGR+8.2%

10Y CAGR+4.9%

Haemonetics Corporation generated $339.4M in revenue in Q1 2027. This represents an increase of 5.6% from the same quarter a year earlier. Against the prior quarter it is down 2.0%.

EBITDA

$84.6M

YoY+2.3%

QoQ+1869.5%

5Y CAGR+26.2%

10Y CAGR+19.2%

Haemonetics Corporation's EBITDA was $84.6M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2.3% from the same quarter a year earlier. Against the prior quarter it is up 1869.5%.

Net Income

$33.0M

YoY-3.0%

QoQn/m

5Y CAGRn/m

10Y CAGRn/m

Haemonetics Corporation reported $33.0M in net income in Q1 2027. This represents a decrease of 3.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

$0.72

YoY+2.9%

QoQn/m

5Y CAGRn/m

10Y CAGRn/m

Haemonetics Corporation earned $0.72 per diluted share (EPS) in Q1 2027. This represents an increase of 2.9% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow

$44.4M

YoY+225.6%

QoQ-16.6%

5Y CAGRn/m

10Y CAGR+18.4%

Haemonetics Corporation generated $44.4M in free cash flow in Q1 2027, representing cash available after capex. This represents an increase of 225.6% from the same quarter a year earlier. Against the prior quarter it is down 16.6%.

Cash & Debt

$223.4M

YoY-23.7%

QoQ-9.0%

5Y CAGR+5.2%

10Y CAGR+6.6%

Haemonetics Corporation held $223.4M in cash against $1.2B in long-term debt as of Q1 2027.

Shares Outstanding

45M

YoY-5.6%

QoQ+0.1%

5Y CAGR-2.3%

10Y CAGR-1.2%

Haemonetics Corporation had 45M shares outstanding in Q1 2027. This represents a decrease of 5.6% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Gross Margin

59.8%

YoY-0.1pp

QoQ+2.5pp

5Y change+12.5pp

10Y change+16.4pp

Haemonetics Corporation's gross margin was 59.8% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.5 percentage points.

Operating Margin

16.9%

YoY+0.2pp

QoQ+23.6pp

5Y change+16.3pp

10Y change+20.7pp

Haemonetics Corporation's operating margin was 16.9% in Q1 2027, reflecting core business profitability. This is up 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 23.6 percentage points.

Net Margin

9.7%

YoY-0.9pp

QoQ+15.6pp

5Y change+11.7pp

10Y change+14.7pp

Haemonetics Corporation's net profit margin was 9.7% in Q1 2027, showing the share of revenue converted to profit. This is down 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 15.6 percentage points.

Return on Equity

3.9%

YoY+0.1pp

QoQ+6.5pp

5Y change+4.6pp

10Y change+5.4pp

Haemonetics Corporation's quarterly ROE was 3.9% in Q1 2027: one quarter's net income over shareholder equity, not annualized. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.5 percentage points.

Capital Allocation

R&D Spending

$16.2M

YoY-0.4%

QoQ+12.1%

5Y CAGR+5.0%

Haemonetics Corporation invested $16.2M in research and development in Q1 2027. This represents a decrease of 0.4% from the same quarter a year earlier. Against the prior quarter it is up 12.1%.

Capital Expenditures

$7.9M

YoY+110.6%

QoQ-55.2%

5Y CAGR-10.7%

10Y CAGR-9.9%

Haemonetics Corporation invested $7.9M in capex in Q1 2027, funding long-term assets and infrastructure. This represents an increase of 110.6% from the same quarter a year earlier. Against the prior quarter it is down 55.2%.

Share Buybacks

Not reported for Q1 2027.

HAE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HAE quarterly income statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$1.4B	$1.3B-2.0%	$1.4B+4.0%	$1.3B+12.0%	$1.2B+17.7%	$993.2M+14.1%	$870.5M-11.9%	$988.5M+2.2%	$967.6M+7.0%	$903.9M+2.0%	$886.1M-2.5%	$908.8M-0.2%	$910.4M-3.0%	$938.5M+5.2%	$892.0M+22.6%	$727.8M
Cost of Revenue	$553.9M	$546.4M-10.7%	$611.9M-0.9%	$617.5M+11.6%	$553.6M+13.5%	$487.7M+3.2%	$472.6M-6.2%	$504.0M-8.4%	$550.0M+11.8%	$492.0M-3.1%	$507.6M+0.9%	$502.9M+5.7%	$476.0M+1.2%	$470.1M+1.4%	$463.9M+29.4%	$358.6M
Gross Profit	$798.1M	$787.6M+5.2%	$749.0M+8.3%	$691.5M+12.4%	$615.1M+21.7%	$505.5M+27.1%	$397.8M-17.9%	$484.5M+16.0%	$417.5M+1.4%	$411.9M+8.8%	$378.5M-6.8%	$405.9M-6.6%	$434.4M-7.2%	$468.4M+9.4%	$428.1M+15.9%	$369.2M
R&D Expenses	$59.7M	$59.8M-4.7%	$62.7M+15.2%	$54.4M+8.6%	$50.1M+7.1%	$46.8M+42.4%	$32.9M+6.4%	$30.9M-13.5%	$35.7M-9.0%	$39.2M+4.5%	$37.6M-16.5%	$45.0M-17.0%	$54.2M0.0%	$54.2M+22.1%	$44.4M+20.6%	$36.8M
SG&A Expenses	$450.6M	$442.4M+1.3%	$436.8M+1.6%	$429.8M+14.1%	$376.7M+10.7%	$340.1M+23.6%	$275.2M-2.4%	$282.0M+3.1%	$273.5M-13.6%	$316.5M+4.9%	$301.7M-4.9%	$317.2M-5.9%	$337.2M-7.9%	$366.0M+13.3%	$323.1M+32.6%	$243.7M
Operating Income	$160.3M	$156.7M-29.3%	$221.8M+34.5%	$164.9M+5.7%	$156.0M+93.2%	$80.8M-10.0%	$89.7M-13.2%	$103.4M+23.7%	$83.5M+48.8%	$56.2Mn/m	-$19.4Mn/m	-$43.9M-208.4%	$40.5M-12.7%	$46.4M-17.7%	$56.4M-36.4%	$88.8M
EBITDA	N/A	$268.5M-20.4%	$337.4M+28.7%	$262.1M+5.1%	$249.3M+39.7%	$178.5M+2.6%	$174.0M-18.5%	$213.6M+10.7%	$193.0M+32.7%	$145.4M+106.7%	$70.4M+53.0%	$46.0M-63.7%	$126.6M-1.2%	$128.2M+5.1%	$121.9M-12.1%	$138.7M
Interest Expense	N/A	$19.3M-46.2%	$35.9M+84.1%	$19.5M+50.0%	$13.0M+124.1%	$5.8M-38.3%	$9.4M-30.4%	$13.5M+7.1%	$12.6M+63.6%	$7.7M	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$34.1M	$30.7M-30.8%	$44.4M+29.4%	$34.3M+31.9%	$26.0M+28.4%	$20.3Mn/m	-$6.6M-161.7%	$10.6M-42.9%	$18.6M+32.4%	$14.1Mn/m	-$1.2M-155.8%	$2.2M-84.8%	$14.3M+1038.7%	$1.3M-88.7%	$11.1M-50.9%	$22.6M
Net Income	$96.3M	$97.3M-42.0%	$167.7M+42.6%	$117.6M+1.9%	$115.4M+166.1%	$43.4M-45.4%	$79.5M+3.8%	$76.5M+39.1%	$55.0M+20.7%	$45.6Mn/m	-$26.3Mn/m	-$55.6M-428.9%	$16.9M-51.9%	$35.1M-9.4%	$38.8M-42.0%	$66.9M
EPS (Basic)	N/A	$2.06-38.1%	$3.33+43.5%	$2.32+2.2%	$2.27+167.1%	$0.85-45.9%	$1.57+4.0%	$1.51+41.1%	$1.07+24.4%	$0.86n/m	-$0.51n/m	-$1.09-430.3%	$0.33-51.5%	$0.68-10.5%	$0.76	$1.32
EPS (Diluted)	$2.07	$2.05-38.1%	$3.31+44.5%	$2.29+2.2%	$2.24+166.7%	$0.84-45.8%	$1.55+4.7%	$1.48+42.3%	$1.04+22.4%	$0.85n/m	-$0.51n/m	-$1.09-440.6%	$0.32-52.2%	$0.67-9.5%	$0.74	$1.30
Diluted Shares (Avg)	N/A	47M-6.7%	51M-1.3%	51M0.0%	51M+0.1%	51M+0.1%	51M-1.0%	52M-2.1%	53M-1.0%	54M+3.8%	52M+1.2%	51M-2.3%	52M-0.5%	52M+0.2%	52M	52M

Metric	Q1'2710-Q	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$339.4M+5.6%	$346.4M+4.8%	$339.0M-2.7%	$327.3M-5.3%	$321.4M-4.4%	$330.6M-3.7%	$348.5M+3.7%	$345.5M+8.6%
Cost of Revenue	$136.6M+5.8%	$148.1M+7.7%	$136.6M-11.9%	$132.6M-16.1%	$129.2M-19.9%	$137.5M-17.8%	$155.0M-2.1%	$158.1M+7.0%
Gross Profit	$202.8M+5.5%	$198.2M+2.7%	$202.4M+4.6%	$194.7M+3.9%	$192.2M+9.9%	$193.1M+9.7%	$193.5M+8.8%	$187.4M+9.9%
R&D Expenses	$16.2M-0.4%	$14.4M-21.1%	$14.2M-10.4%	$14.9M+5.2%	$16.3M+12.5%	$18.3M+15.4%	$15.8M+19.3%	$14.1M+11.6%
SG&A Expenses	$118.9M+7.4%	$120.9M+5.0%	$109.2M+2.5%	$101.6M-5.0%	$110.7M+2.3%	$115.1M+5.4%	$106.5M-4.7%	$106.9M-7.3%
Operating Income	$57.5M+6.7%	-$23.0M-132.3%	$67.4M+14.2%	$58.5M+13.1%	$53.9M+35.5%	$71.3M+138.2%	$59.0M+28.4%	$51.7M+46.4%
EBITDA	$84.6M+2.3%	$4.3M-95.7%	$94.8M+7.6%	$86.7M+7.2%	$82.6M+19.9%	$99.5M+72.7%	$88.1M+26.7%	$80.9M+38.8%
Income Tax	$14.6M+30.8%	-$8.3M-164.7%	$15.2M+22.6%	$12.6M+15.9%	$11.1M+33.5%	$12.8M+318.6%	$12.4M-2.9%	$10.9M+37.2%
Net Income	$33.0M-3.0%	-$20.1M-134.7%	$44.7M+19.3%	$38.7M+14.3%	$34.0M-11.3%	$58.0M+184.7%	$37.5M+20.0%	$33.8M+35.8%
EPS (Basic)	$0.73+2.8%	-$0.41-135.0%	$0.96+28.0%	$0.81+22.7%	$0.71-5.3%	$1.17+192.5%	$0.75+21.0%	$0.66+34.7%
EPS (Diluted)	$0.72+2.9%	-$0.41-135.0%	$0.95+28.4%	$0.81+22.7%	$0.70-5.4%	$1.17+192.5%	$0.74+21.3%	$0.66+37.5%
Diluted Shares (Avg)	46M-5.5%	N/A	47M-7.2%	48M-7.0%	48M-6.2%	N/A	51M-1.6%	51M-0.3%

Not reported in any period shown, so not listed: Interest Expense.

HAE Balance Sheet

HAE quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$2.4B-2.2%	$2.5B+11.6%	$2.2B+13.5%	$1.9B+4.0%	$1.9B+2.2%	$1.8B+43.6%	$1.3B-0.6%	$1.3B+3.0%	$1.2B-0.1%	$1.2B-6.1%	$1.3B-11.2%	$1.5B-1.9%	$1.5B+3.6%	$1.5B+60.5%	$911.1M
Current Assets	$834.9M-10.7%	$935.0M+21.6%	$768.9M-0.1%	$769.7M+1.8%	$756.0M+9.0%	$693.5M+14.9%	$603.6M+4.8%	$576.1M+10.5%	$521.2M+2.2%	$510.0M+4.5%	$488.1M-12.5%	$557.7M-10.5%	$623.0M+4.3%	$597.0M+13.3%	$527.1M
Cash & Equivalents	$245.4M-20.0%	$306.8M+71.6%	$178.8M-37.1%	$284.5M+9.6%	$259.5M+34.9%	$192.3M+40.1%	$137.3M-18.9%	$169.4M-6.0%	$180.2M+29.1%	$139.6M+21.2%	$115.1M-28.3%	$160.7M-16.5%	$192.5M+7.5%	$179.1M-21.7%	$228.9M
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Inventory	$306.4M-16.1%	$365.1M+15.1%	$317.2M+22.3%	$259.4M-11.5%	$293.0M-9.2%	$322.6M+19.4%	$270.3M+39.1%	$194.3M+20.9%	$160.8M-9.1%	$176.9M-5.4%	$187.0M-11.4%	$211.1M+6.8%	$197.7M+7.6%	$183.8M+56.9%	$117.2M
Accounts Receivable	$216.9M+7.0%	$202.7M-1.9%	$206.6M+15.3%	$179.1M+12.4%	$159.4M+24.9%	$127.6M-22.8%	$165.2M-10.7%	$185.0M+22.4%	$151.2M-1.0%	$152.7M-2.8%	$157.1M+7.7%	$145.8M-11.4%	$164.6M-3.2%	$170.1M+25.6%	$135.5M
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	$656.4M+8.6%	$604.3M+6.9%	$565.1M+21.2%	$466.2M-0.2%	$467.3M+0.2%	$466.4M+121.4%	$210.7M-0.1%	$210.8M-0.3%	$211.4M+0.3%	$210.8M-21.3%	$267.8M-19.9%	$334.3M-0.7%	$336.8M+1.9%	$330.5M+187.2%	$115.1M
Total Liabilities	$1.6B-1.9%	$1.6B+31.9%	$1.2B+10.6%	$1.1B+0.6%	$1.1B+2.0%	$1.1B+60.0%	$680.0M+12.0%	$606.9M+25.2%	$484.9M-2.8%	$499.1M-16.5%	$597.6M-9.4%	$659.3M-2.5%	$676.3M-2.4%	$692.7M+288.1%	$178.5M
Current Liabilities	$282.6M-51.1%	$578.1M+92.5%	$300.4M+19.3%	$251.8M-43.1%	$442.3M+74.5%	$253.5M-7.8%	$274.8M+16.6%	$235.8M-38.7%	$384.7M+82.2%	$211.2M+13.8%	$185.6M-1.7%	$188.7M-13.0%	$216.9M+20.4%	$180.1M+37.8%	$130.7M
Non-Current Liabilities	$1.3B+25.2%	$1.1B+12.5%	$935.2M+8.1%	$865.0M+29.5%	$668.0M-20.0%	$834.8M+106.0%	$405.2M+9.2%	$371.1M+270.4%	$100.2M-65.2%	$287.9M-30.1%	$412.0M-12.5%	$470.6M+2.4%	$459.4M-10.4%	$512.6M+973.3%	$47.8M
Long-Term Debt	$1.2B+32.4%	$921.2M+15.5%	$797.6M+5.8%	$754.1M+34.8%	$559.4M-19.0%	$690.6M+126.0%	$305.5M-5.3%	$322.5M+442.6%	$59.4M-76.6%	$253.6M-30.4%	$364.5M-10.3%	$406.4M+3.7%	$392.1M-14.2%	$456.9M+15782.7%	$2.9M
Total Equity	$796.3M-3.0%	$820.8M-14.5%	$960.0M+17.4%	$818.0M+9.2%	$749.4M+2.4%	$731.7M+24.6%	$587.1M-12.1%	$667.9M-11.2%	$752.4M+1.7%	$739.6M+2.5%	$721.6M-12.7%	$826.1M-1.4%	$837.9M+8.9%	$769.2M+5.0%	$732.6M
Retained Earnings	$279.3M-20.7%	$352.2M-2.3%	$360.5M+42.4%	$253.2M+25.1%	$202.4M+28.1%	$158.0M+101.2%	$78.5M-51.4%	$161.4M-39.5%	$266.9M-7.9%	$289.9M-8.3%	$316.2M-24.8%	$420.4M-3.0%	$433.3M+8.8%	$398.2M-0.6%	$400.8M

Metric	Q1'2710-Q	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$2.4B-3.9%	$2.4B-2.2%	$2.5B-1.6%	$2.4B-3.3%	$2.5B-3.1%	$2.5B+11.6%	$2.5B+15.0%	$2.5B+25.6%
Current Assets	$810.8M-11.2%	$834.9M-10.7%	$943.7M-6.2%	$899.7M-5.9%	$913.2M-6.7%	$935.0M+21.6%	$1.0B+31.5%	$955.9M+10.4%
Cash & Equivalents	$223.4M-23.7%	$245.4M-20.0%	$363.4M+13.3%	$296.4M-1.0%	$292.9M-15.0%	$306.8M+71.6%	$320.8M+65.4%	$299.3M-14.7%
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Inventory	$306.7M-14.9%	$306.4M-16.1%	$321.2M-10.7%	$336.2M-12.0%	$360.5M-3.5%	$365.1M+15.1%	$359.6M+18.3%	$382.1M+33.7%
Accounts Receivable	$216.1M+7.6%	$216.9M+7.0%	$195.7M-7.7%	$207.1M-3.0%	$200.8M-0.4%	$202.7M-1.9%	$211.9M+0.2%	$213.5M+22.5%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Goodwill	$656.9M+8.2%	$656.4M+8.6%	$606.8M+0.3%	$606.1M-1.6%	$607.3M-1.0%	$604.3M+6.9%	$605.3M+9.1%	$616.2M+32.4%
Total Liabilities	$1.5B-3.3%	$1.6B-1.9%	$1.6B-2.8%	$1.6B-3.2%	$1.6B-3.4%	$1.6B+31.9%	$1.6B+29.2%	$1.6B+47.3%
Current Liabilities	$263.2M-50.5%	$282.6M-51.1%	$539.9M+113.2%	$548.3M+100.2%	$531.4M+104.3%	$578.1M+92.5%	$253.2M-3.3%	$273.9M+3.7%
Non-Current Liabilities	$1.3B+20.7%	$1.3B+25.2%	$1.0B-24.2%	$1.0B-23.9%	$1.0B-23.8%	$1.1B+12.5%	$1.4B+37.8%	$1.4B+60.8%
Long-Term Debt	$1.2B+27.0%	$1.2B+32.4%	$920.0M-24.6%	$920.4M-24.5%	$920.8M-24.4%	$921.2M+15.5%	$1.2B+42.4%	$1.2B+62.9%
Total Equity	$837.1M-5.1%	$796.3M-3.0%	$911.5M+0.5%	$849.2M-3.4%	$882.3M-2.5%	$820.8M-14.5%	$906.9M-3.9%	$878.9M-1.7%
Retained Earnings	$311.5M-12.5%	$279.3M-20.7%	$381.1M-2.8%	$336.3M-8.7%	$356.0M-7.9%	$352.2M-2.3%	$392.2M+15.3%	$368.5M+19.3%

HAE Cash Flow Statement

HAE quarterly cash flow statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$328.1M	$293.2M+61.4%	$181.7M0.0%	$181.8M-33.4%	$273.1M+58.5%	$172.3M+58.3%	$108.8M-31.2%	$158.2M-0.7%	$159.3M-27.7%	$220.3M+37.9%	$159.7M+31.1%	$121.9M-4.2%	$127.2M-8.8%	$139.5M+64.0%	$85.1M-26.2%	$115.3M
Depreciation & Amortization	N/A	$111.7M-3.3%	$115.6M+18.9%	$97.2M+4.2%	$93.3M-4.5%	$97.7M+16.0%	$84.3M-23.6%	$110.3M+0.8%	$109.4M+22.6%	$89.2M-0.5%	$89.7M-0.2%	$89.9M+4.5%	$86.1M+5.3%	$81.7M+24.8%	$65.5M+31.1%	$50.0M
Stock-Based Compensation	N/A	$33.8M+14.1%	$29.6M+4.6%	$28.3M+10.7%	$25.6M+5.0%	$24.4M-4.5%	$25.5M+24.7%	$20.5M+19.0%	$17.2M+32.0%	$13.0M+42.3%	$9.2M+31.7%	$6.9M-50.7%	$14.1M+7.7%	$13.1M+19.3%	$11.0M+18.1%	$9.3M
Capital Expenditures	$36.9M	$32.8M-16.5%	$39.3M+3.0%	$38.1M-80.1%	$191.3M+98.2%	$96.5M+160.6%	$37.0M-24.0%	$48.8M-59.0%	$119.0M+59.0%	$74.8M-1.8%	$76.1M-25.7%	$102.4M-16.2%	$122.2M+66.0%	$73.6M+18.4%	$62.2M+16.9%	$53.2M
Free Cash Flow	$291.2M	$260.4M+82.8%	$142.4M-0.8%	$143.6M+75.7%	$81.7M+7.9%	$75.8M+5.6%	$71.8M-34.4%	$109.5M+171.5%	$40.3M-72.3%	$145.6M+74.1%	$83.6M+329.6%	$19.5M+292.5%	$5.0M-92.5%	$65.9M+187.8%	$22.9M-63.2%	$62.1M
Investing Cash Flow	-$168.8M	-$179.5Mn/m	-$161.9Mn/m	-$322.4Mn/m	-$143.8Mn/m	-$86.3Mn/m	-$425.4Mn/m	-$57.2Mn/m	-$116.1Mn/m	-$63.0Mn/m	-$73.3Mn/m	-$104.8Mn/m	-$121.8Mn/m	-$105.8Mn/m	-$596.4Mn/m	-$52.2M
Financing Cash Flow	-$227.5M	-$178.5M-264.0%	$108.8M+185.2%	$38.2Mn/m	-$100.4Mn/m	-$15.7M-104.3%	$367.5Mn/m	-$131.2Mn/m	-$50.6Mn/m	-$120.6Mn/m	-$60.4Mn/m	-$62.6Mn/m	-$33.2Mn/m	-$20.7M-104.5%	$461.9Mn/m	-$30.5M
Share Buybacks	N/A	$175.0M-22.2%	$225.0Mn/m	$0-100.0%	$75.0Mn/m	$0n/m	$0-100.0%	$175.0M+9.4%	$160.0M+60.0%	$100.0Mn/m	$0-100.0%	$61.0M+56.2%	$39.0Mn/m	$0-100.0%	$50.0M0.0%	$50.0M

Metric	Q1'2710-Q	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	$52.3M+200.8%	$70.9M-39.1%	$93.6M+113.8%	$111.3M+128.0%	$17.4Mn/m	$116.6M+81.9%	$43.8Mn/m	$48.8M-50.7%
Depreciation & Amortization	$27.1M-5.7%	$27.3M-3.2%	$27.4M-5.7%	$28.3M-3.3%	$28.8M-1.3%	$28.2M+2.1%	$29.0M+23.5%	$29.2M+27.0%
Stock-Based Compensation	$9.3M0.0%	N/A	$7.8M-5.1%	$7.6M+10.7%	$9.3M+22.1%	N/A	$8.2M	$6.9M
Capital Expenditures	$7.9M+110.6%	$17.7M+12.9%	$6.3M-25.7%	$5.0M-46.8%	$3.8M-33.6%	$15.6M+134.0%	$8.5M-41.6%	$9.4M+3.5%
Free Cash Flow	$44.4M+225.6%	$53.3M-47.2%	$87.2M+147.6%	$106.3M+169.9%	$13.6Mn/m	$100.9M+75.8%	$35.2Mn/m	$39.4M-56.2%
Investing Cash Flow	-$22.2Mn/m	-$86.6M-580.1%	-$29.5Mn/m	-$30.5Mn/m	-$33.0Mn/m	$18.0Mn/m	-$17.4Mn/m	-$23.4Mn/m
Financing Cash Flow	-$51.5Mn/m	-$101.5Mn/m	$2.0M+47.3%	-$76.6Mn/m	-$2.4M-100.7%	-$151.4Mn/m	$1.4M-98.7%	-$74.8Mn/m
Share Buybacks	N/A	$100.0M-33.3%	$0n/m	N/A	N/A	$150.0Mn/m	$0n/m	N/A

Not reported in any period shown, so not listed: Dividends Paid.

HAE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HAE quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	59.0%+4.0pp	55.0%+2.2pp	52.8%+0.2pp	52.6%+1.7pp	50.9%+5.2pp	45.7%-3.3pp	49.0%+5.9pp	43.1%-2.4pp	45.6%+2.9pp	42.7%-2.0pp	44.7%-3.1pp	47.7%-2.2pp	49.9%+1.9pp	48.0%-2.7pp	50.7%
Operating Margin	11.8%-4.6pp	16.3%+3.7pp	12.6%-0.8pp	13.4%+5.2pp	8.1%-2.2pp	10.3%-0.2pp	10.5%+1.8pp	8.6%+2.4pp	6.2%+8.4pp	-2.2%+2.6pp	-4.8%-9.3pp	4.5%-0.5pp	5.0%-1.4pp	6.3%-5.9pp	12.2%
Net Margin	7.3%-5.0pp	12.3%+3.3pp	9.0%-0.9pp	9.9%+5.5pp	4.4%-4.8pp	9.1%+1.4pp	7.7%+2.0pp	5.7%+0.6pp	5.0%+8.0pp	-3.0%+3.2pp	-6.1%-8.0pp	1.9%-1.9pp	3.8%-0.6pp	4.3%-4.8pp	9.2%
Return on Equity	12.2%-8.2pp	20.4%+8.2pp	12.3%-1.9pp	14.1%+8.3pp	5.8%-5.1pp	10.9%-2.2pp	13.0%+4.8pp	8.2%+2.2pp	6.1%+9.6pp	-3.5%+4.2pp	-7.7%-9.8pp	2.1%-2.1pp	4.2%-0.9pp	5.0%-4.1pp	9.1%
Return on Assets	4.1%-2.8pp	6.8%+1.5pp	5.3%-0.6pp	6.0%+3.6pp	2.3%-2.0pp	4.4%-1.7pp	6.0%+1.7pp	4.3%+0.6pp	3.7%+5.8pp	-2.1%+2.1pp	-4.2%-5.3pp	1.1%-1.2pp	2.3%-0.3pp	2.6%-4.7pp	7.3%
Current Ratio	2.95+1.3x	1.62-0.9x	2.56-0.5x	3.06+1.3x	1.71-1.0x	2.74+0.5x	2.20-0.2x	2.44+1.1x	1.35-1.1x	2.42-0.2x	2.63-0.3x	2.96+0.1x	2.87-0.4x	3.31-0.7x	4.03
Debt-to-Equity	1.53+0.4x	1.12+0.3x	0.83-0.1x	0.92+0.2x	0.75-0.2x	0.94+0.4x	0.520.0x	0.48+0.4x	0.08-0.3x	0.34-0.2x	0.510.0x	0.490.0x	0.47-0.1x	0.59+0.6x	0.00
Liabilities-to-Equity	2.010.0x	1.99+0.7x	1.29-0.1x	1.37-0.1x	1.480.0x	1.49+0.3x	1.16+0.2x	0.91+0.3x	0.640.0x	0.67-0.2x	0.830.0x	0.800.0x	0.81-0.1x	0.90+0.7x	0.24
Asset Turnover	0.560.0x	0.560.0x	0.600.0x	0.60+0.1x	0.53+0.1x	0.48-0.3x	0.780.0x	0.760.0x	0.730.0x	0.720.0x	0.69+0.1x	0.610.0x	0.620.0x	0.61-0.2x	0.80
FCF Margin	19.5%+9.1pp	10.5%-0.5pp	11.0%+4.0pp	7.0%-0.6pp	7.6%-0.6pp	8.2%-2.8pp	11.1%+6.9pp	4.2%-11.9pp	16.1%+6.7pp	9.4%+7.3pp	2.1%+1.6pp	0.5%-6.5pp	7.0%+4.5pp	2.6%-6.0pp	8.5%

Metric	Q1'2710-Q	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Gross Margin	59.8%-0.1pp	57.2%-1.2pp	59.7%+4.2pp	59.5%+5.2pp	59.8%+7.8pp	58.4%+7.2pp	55.5%+2.6pp	54.3%+0.7pp
Operating Margin	16.9%+0.2pp	-6.7%-28.2pp	19.9%+2.9pp	17.9%+2.9pp	16.8%+4.9pp	21.6%+12.9pp	16.9%+3.3pp	15.0%+3.9pp
Net Margin	9.7%-0.9pp	-5.8%-23.4pp	13.2%+2.4pp	11.8%+2.0pp	10.6%-0.8pp	17.5%+11.6pp	10.8%+1.5pp	9.8%+2.0pp
Return on Equity	3.9%+0.1pp	-2.5%-9.6pp	4.9%+0.8pp	4.6%+0.7pp	3.9%-0.4pp	7.1%+4.9pp	4.1%+0.8pp	3.9%+1.1pp
Return on Assets	1.4%0.0pp	-0.8%-3.2pp	1.8%+0.3pp	1.6%+0.2pp	1.4%-0.1pp	2.4%+1.4pp	1.5%+0.1pp	1.3%+0.1pp
Current Ratio	3.08+1.4x	2.95+1.3x	1.75-2.2x	1.64-1.8x	1.72-2.0x	1.62-0.9x	3.97+1.0x	3.49+0.2x
Debt-to-Equity	1.40+0.4x	1.53+0.4x	1.01-0.3x	1.08-0.3x	1.04-0.3x	1.12+0.3x	1.34+0.4x	1.39+0.5x
Liabilities-to-Equity	1.830.0x	2.010.0x	1.73-0.1x	1.880.0x	1.790.0x	1.99+0.7x	1.79+0.5x	1.87+0.6x
Asset Turnover	0.140.0x	0.140.0x	0.140.0x	0.130.0x	0.130.0x	0.130.0x	0.140.0x	0.140.0x
FCF Margin	13.1%+8.8pp	15.4%-15.1pp	25.7%+15.6pp	32.5%+21.1pp	4.2%+14.1pp	30.5%+13.8pp	10.1%+14.6pp	11.4%-16.9pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Haemonetics Corporation HAE	FY2026	$1.3B	$97.3M	7.3%	$5.4B	58/100
Inspire Medical Systems, Inc. INSP	FY2025	$912.0M	$145.4M	16.0%	$2.1B	63/100
Alphatec Holdings, Inc. ATEC	FY2025	$764.2M	-$143.4M	-18.8%	$1.7B	36/100
Integer Holdings Corporation ITGR	FY2025	$1.9B	$102.8M	5.5%	$4.3B	58/100
LivaNova PLC LIVN	FY2025	$1.4B	-$242.5M	-17.5%	$4.4B	58/100
PROCEPT BioRobotics Corporation PRCT	FY2025	$308.1M	-$95.6M	-31.0%	$1.1B	54/100

Where Haemonetics Corporation Ranks

Frequently Asked Questions

What is Haemonetics Corporation's annual revenue?

Haemonetics Corporation (HAE) reported $1.3B in total revenue for fiscal year 2026. This represents a -2.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Haemonetics Corporation's revenue growing?

Haemonetics Corporation (HAE) revenue declined by 2.0% year-over-year, from $1.4B to $1.3B in fiscal year 2026.

Is Haemonetics Corporation profitable?

Yes, Haemonetics Corporation (HAE) reported a net income of $96.3M over the trailing 12 months to June 27, 2026. In fiscal year 2026 it reported a net income of $97.3M, with a net profit margin of 7.3%.

What is Haemonetics Corporation's EBITDA?

Haemonetics Corporation (HAE) had EBITDA of $268.5M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Haemonetics Corporation have?

As of fiscal year 2026, Haemonetics Corporation (HAE) had $245.4M in cash and equivalents against $1.2B in long-term debt.

What is Haemonetics Corporation's gross margin?

Haemonetics Corporation (HAE) had a gross margin of 59.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Haemonetics Corporation's operating margin?

Haemonetics Corporation (HAE) had an operating margin of 11.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Haemonetics Corporation's net profit margin?

Haemonetics Corporation (HAE) had a net profit margin of 7.3% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Haemonetics Corporation's return on equity (ROE)?

Haemonetics Corporation (HAE) has a return on equity of 12.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Haemonetics Corporation's free cash flow?

Haemonetics Corporation (HAE) generated $260.4M in free cash flow during fiscal year 2026. This represents a 82.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Haemonetics Corporation's operating cash flow?

Haemonetics Corporation (HAE) generated $293.2M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Haemonetics Corporation's total assets?

Haemonetics Corporation (HAE) had $2.4B in total assets as of fiscal year 2026, including both current and long-term assets.

What are Haemonetics Corporation's capital expenditures?

Haemonetics Corporation (HAE) invested $32.8M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Haemonetics Corporation spend on research and development?

Haemonetics Corporation (HAE) invested $59.8M in research and development during fiscal year 2026.

Does Haemonetics Corporation buy back shares?

Yes, Haemonetics Corporation (HAE) spent $175.0M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Haemonetics Corporation have outstanding?

Haemonetics Corporation (HAE) had 45M shares outstanding as of fiscal year 2026.

What is Haemonetics Corporation's current ratio?

Haemonetics Corporation (HAE) had a current ratio of 2.95 as of fiscal year 2026, which is generally considered healthy.

What is Haemonetics Corporation's debt-to-equity ratio?

Haemonetics Corporation (HAE) had a debt-to-equity ratio of 1.53 as of fiscal year 2026. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

What is Haemonetics Corporation's liabilities-to-equity ratio?

Haemonetics Corporation (HAE) had a liabilities-to-equity ratio of 2.01 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

What is Haemonetics Corporation's return on assets (ROA)?

Haemonetics Corporation (HAE) had a return on assets of 4.1% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Haemonetics Corporation's P/E ratio?

Haemonetics Corporation (HAE) trades at 56.3x earnings, its market capitalization divided by $96.3M net income, trailing 12 months to June 27, 2026. The market capitalization is $5.4B as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Haemonetics Corporation's price-to-sales ratio?

Haemonetics Corporation (HAE) trades at 4.0x sales, its market capitalization divided by $1.4B revenue, trailing 12 months to June 27, 2026. The market capitalization is $5.4B as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Haemonetics Corporation's Altman Z-Score?

Haemonetics Corporation (HAE) has an Altman Z-Score of 3.25, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Haemonetics Corporation's Piotroski F-Score?

Haemonetics Corporation (HAE) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Haemonetics Corporation's earnings high quality?

Haemonetics Corporation (HAE) has an earnings quality ratio of 3.01x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Haemonetics Corporation cover its interest payments?

Haemonetics Corporation (HAE) has an interest coverage ratio of 8.12x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Haemonetics Corporation?

Haemonetics Corporation (HAE) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.